Novartis at ASCO 2024
The 2024 ASCO Annual Meeting Program will feature over 200 sessions complementing Dr. Lynn Schuchter’s Presidential theme: The Art and Science of Cancer Care: From Comfort to Cure.
Start Date/Time
06:00, CEST, May 30, 2024
End Date/Time
16:00, CEST, June 3, 2024
Session Summary
At ASCO this year, Novartis will share new data from our robust portfolio and pipeline of advanced therapeutic platforms in cancer and blood disorders, showcasing the impact of our bold science in research.a
Date/Time
23:00, CDT, May 29, 2024 - 00:00, CDT, May 30, 2024
Location
McCormick Place, Chicago
United States
Venue 1
In person: McCormick Place, Chicago
Venue 2
Online: See Resources below
Resources
Session Summary
A presentation on Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.
NATALEE assessed ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) vs NSAI alone in pts with HR+/HER2− EBC at increased risk of recurrence, including pts with N0 disease, and showed a statistically significant invasive disease-free survival (iDFS) benefit.
We report BL characteristics, efficacy, and safety for the N0 subgroup.
Date/Time
00:00, CDT, June 1, 2024 - 01:00, CDT, June 1, 2024
Location
United States
Venue 1
In-person: McCormick Place, Chicago
Venue 2
Remove: See resource for webcast
Session Summary
A presentation on ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.
Novartis presents primary results from ASC4FIRST (NCT04971226), the first study in CML comparing all current standard-of-care frontline TKIs with a novel agent, ASC, in newly diagnosed pts. ASC Specifically Targets the ABL Myristoyl Pocket (STAMP).
Date/Time
00:00, CDT, June 2, 2024 - 02:00, CDT, June 2, 2024
Location
McCormick Place, Chicago
United States
